Sun Pharma reports UNLOXCYT designation: October 30 results will test Sun Pharma stock

Published on 10/22/2026 at 09:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UNLOXCYT received Category 2A status on October 20, 2026. Sun Pharma stock faces INR 158.25 billion revenue estimates for October 30.

Pipeline and financing update

UNLOXCYT received Category 2A preferred designation on October 20, 2026, after a 55.00 percent objective response.
Sun Pharma reported INR 153.0 billion in first-quarter fiscal 2027 revenue, up 10.50 percent year over year.
Second-quarter results are scheduled for October 30, 2026, with INR 158.25 billion in consensus revenue.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma (INE044A01036) said UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines on October 20, 2026, after a pivotal study showed a 55.00 percent objective response. Indian Stock Alerts reported the filing, while October 30 results will provide the next quantified test for the company.

Three events reshape the story

On October 7, 2026, Sun Pharma considered a non-convertible debenture program of up to INR 100.0 billion. On October 12, 2026, the board approved a private placement of up to INR 100.0 billion, according to StockFin. On October 20, 2026, UNLOXCYT received the Category 2A designation after the 55.00 percent response rate reported in the study.

What do the estimates imply?

The latest reported quarter gives investors a strong comparison point. Sun Pharma generated INR 153.0 billion of revenue in the first quarter of fiscal 2027, up 10.50 percent from the prior-year quarter, while net income reached INR 28.95 billion, according to StockFin.

For the quarter ended September 30, 2026, 23 analysts estimated revenue of INR 158.25 billion, 9.30 percent above the prior-year quarter, while 13 analysts expected earnings per share of INR 12.94 versus INR 13.00 previously. finanzen.ch published those estimates on October 16, 2026.

Dates investors can quantify

The next dated event is October 30, 2026, when Sun Pharma is scheduled to report results for the quarter ended September 30, 2026. The company also scheduled its earnings call for that date, giving investors a defined point for comparing revenue growth with the INR 158.25 billion consensus estimate.

Indian valuation stays measurable

Sun Pharma had a market capitalization of INR 4.2 trillion on October 22, 2026, while its NSE 52-week range stood at INR 1,583.70 to INR 2,046.90. The range places the latest quotation below its yearly high and above its yearly low.

Sun Pharma last stood at INR 1,743.60 on the NSE on October 22, 2026, at 1:28 p.m. IST. That quotation gives the upcoming results a clear market reference without changing the company's longer-term pipeline story.